GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MannKind Corp (NAS:MNKD) » Definitions » Beneish M-Score
中文

MannKind (MannKind) Beneish M-Score : -2.55 (As of Apr. 24, 2024)


View and export this data going back to 2004. Start your Free Trial

MannKind Beneish M-Score Definition

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Good Sign:

Beneish M-Score -2.55 no higher than -1.78, which implies that the company is unlikely to be a manipulator.

The historical rank and industry rank for MannKind's Beneish M-Score or its related term are showing as below:

MNKD' s Beneish M-Score Range Over the Past 10 Years
Min: -10.79   Med: -2.55   Max: 10.6
Current: -2.55

During the past 13 years, the highest Beneish M-Score of MannKind was 10.60. The lowest was -10.79. And the median was -2.55.


MannKind Beneish M-Score Historical Data

The historical data trend for MannKind's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MannKind Beneish M-Score Chart

MannKind Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 10.60 -2.80 0.14 -1.10 -2.55

MannKind Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.10 -2.25 -2.11 -2.79 -2.55

Competitive Comparison of MannKind's Beneish M-Score

For the Biotechnology subindustry, MannKind's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MannKind Beneish M-Score Distribution

For the Biotechnology industry and Healthcare sector, MannKind's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where MannKind's Beneish M-Score falls into.



MannKind Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of MannKind for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.4447+0.528 * 0.619+0.404 * 0.7161+0.892 * 1.9942+0.115 * 1.8936
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.517+4.679 * -0.092736-0.327 * 0.6405
=-2.55

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec23) TTM:Last Year (Dec22) TTM:
Total Receivables was $14.9 Mil.
Revenue was 58.472 + 51.253 + 48.611 + 40.626 = $199.0 Mil.
Gross Profit was 40.405 + 36.999 + 34.374 + 24.413 = $136.2 Mil.
Total Current Assets was $373.4 Mil.
Total Assets was $475.2 Mil.
Property, Plant and Equipment(Net PPE) was $84.2 Mil.
Depreciation, Depletion and Amortization(DDA) was $5.8 Mil.
Selling, General, & Admin. Expense(SGA) was $94.3 Mil.
Total Current Liabilities was $104.1 Mil.
Long-Term Debt & Capital Lease Obligation was $252.6 Mil.
Net Income was 1.401 + 1.721 + -5.265 + -9.795 = $-11.9 Mil.
Non Operating Income was -4.042 + 2.383 + 0.538 + -0.843 = $-2.0 Mil.
Cash Flow from Operations was 21.678 + 8.664 + 2.596 + 1.156 = $34.1 Mil.
Total Receivables was $16.8 Mil.
Revenue was 36.059 + 32.825 + 18.894 + 11.992 = $99.8 Mil.
Gross Profit was 19.935 + 15.365 + 5.979 + 0.994 = $42.3 Mil.
Total Current Assets was $234.9 Mil.
Total Assets was $295.3 Mil.
Property, Plant and Equipment(Net PPE) was $45.1 Mil.
Depreciation, Depletion and Amortization(DDA) was $6.3 Mil.
Selling, General, & Admin. Expense(SGA) was $91.5 Mil.
Total Current Liabilities was $67.3 Mil.
Long-Term Debt & Capital Lease Obligation was $278.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(14.901 / 198.962) / (16.801 / 99.77)
=0.074894 / 0.168397
=0.4447

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(42.273 / 99.77) / (136.191 / 198.962)
=0.423705 / 0.684508
=0.619

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (373.393 + 84.22) / 475.198) / (1 - (234.896 + 45.126) / 295.282)
=0.037006 / 0.051679
=0.7161

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=198.962 / 99.77
=1.9942

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(6.312 / (6.312 + 45.126)) / (5.836 / (5.836 + 84.22))
=0.122711 / 0.064804
=1.8936

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(94.314 / 198.962) / (91.473 / 99.77)
=0.47403 / 0.916839
=0.517

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((252.624 + 104.125) / 475.198) / ((278.833 + 67.296) / 295.282)
=0.750738 / 1.172198
=0.6405

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-11.938 - -1.964 - 34.094) / 475.198
=-0.092736

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

MannKind has a M-score of -2.55 suggests that the company is unlikely to be a manipulator.


MannKind Beneish M-Score Related Terms

Thank you for viewing the detailed overview of MannKind's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


MannKind (MannKind) Business Description

Traded in Other Exchanges
Address
1 Casper Street, Danbury, CT, USA, 06810
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
Executives
Michael Castagna officer: Chief Commercial Officer 25134 RYE CANYON LOOP, SUITE 300, VALENCIA CA 91355
David Thomson officer: VP & Assoc General Counsel 28903 NORTH AVENUE PAINE, VALENCIA CA 91355
Steven B. Binder officer: Chief Financial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Burkhard Blank officer: EVP Chief Medical Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Lauren M Sabella officer: EVP Chief Operating Officer C/O ACORDA THERAPEUTICS, 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
Sanjay R Singh officer: EVP Technical Operations 1 CASPER STREET, DANBURY CT 06810
Alejandro Galindo officer: Chief Commercial Officer 30930 RUSSELL RANCH RD, STE 300, WESTLAKE VILLAGE CA 91362
Stuart A Tross officer: Corp VP, Chief People Officer ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Anthony C Hooper director AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Jennifer Grancio director 30930 RUSSELL RANCH ROAD SUITE 300, WESTLAKE VILLAGE CA 91362
Christine Mundkur director
Sabrina Kay director 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
David M Kendall officer: Chief Medical Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362
Patrick Mccauley officer: Chief Commercial Officer 30930 RUSSELL RANCH ROAD, SUITE 300, WESTLAKE VILLAGE CA 91362
Barton Courtney officer: Chief Compliance Officer 30930 RUSSELL RANCH ROAD, WESTLAKE VILLAGE CA 91362